TF and non-small cell lung carcinoma: Currently the same ADC is under a new Phase 2 trial (NCT03245736) in 25 patients with solid tumors known to express TF, including cancers of the ovary, cervix, endometrium, bladder, prostate, esophagus, lung (non-small cell lung cancer, NSCLC) and head and neck (squamous cell carcinoma).